CompanyDrug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

CompanyDrug

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

CompanyDrug

Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic

CompanyDrug

Lynk Pharma’s Zemprocitinib Hits Phase III Endpoints in Atopic Dermatitis – Best‑in‑Class JAK1 Inhibitor Shows Superior Efficacy

DigitalDrug

ReviR Therapeutics Doses First Patient in RTX-117 Trial – China’s First “AI + RNA” Small Molecule Enters Clinic

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market
CompanyDeals

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

CompanyDrug

Roche’s Fenebrutinib Hits Phase III Endpoint in MS – BTK Inhibitor Cuts Relapse Rate 51% vs. Standard of Care

Sanofi's Rilzabrutinib Wins Japan Orphan Designation for IgG4‑RD – BTK Inhibitor Expands Rare Disease Portfolio
CompanyDrug

Sanofi’s Rilzabrutinib Wins Japan Orphan Designation for IgG4‑RD – BTK Inhibitor Expands Rare Disease Portfolio

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy
CompanyDeals

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

CompanyDrug

CSPC Pharma’s SYHX2011G1 Wins FDA IND Approval – Instant‑Release Albumin‑Bound Paclitaxel for Metastatic Breast Cancer

CompanyDeals

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

CompanyDrug

Gan & Lee’s AR PROTAC GLR2037 Wins NMPA Approval – First‑in‑Class Prostate Cancer Therapy Enters Clinic